Treatment of Moyamoya Disease With iPSC-derived Exosomes

Phase I Clinical Trial of Induced Pluripotent Stem Cell-derived Extracellular Vesicles Combined With Temporal Muscle Flap Application in Promoting Intracranial and Extracranial Blood Flow Reconstruction in Patients With Moyamoya Disease

Moyamoya disease is a cerebrovascular disease clinically characterized by chronic progressive stenosis or occlusion at the ends of bilateral internal carotid arteries and the origin of anterior cerebral arteries and middle cerebral arteries, followed by the formation of abnormal vascular networks at the base of the skull. Clinically, patients with Moyamoya disease mainly present with ischemic or hemorrhagic stroke, and there are two peaks of incidence in children aged 3-5 and middle-aged people aged 40-50. Moreover, as the pathogenesis and treatment evaluation of Moyamoya disease are still in the research trough at present, new discoveries are prone to occur and thus attract a great deal of attention. It not only has a beneficial promoting effect on the treatment and diagnosis of patients, but also makes it easier for research topics to be reported in top journals.

This study intends to combine iPSC-EVs local skin transplantation with temporal muscle application to promote muscle angiogenesis and the establishment of extracranial and intracranial collateral circulation after temporal muscle application. The above-mentioned design features high efficiency, safety and convenience, and is an innovative exploration both at home and abroad. We hope to screen out safe, efficient and simple preparation methods and transplantation methods of iPSC-EVs through systematic experiments, establish an effective clinical evaluation system, and provide auxiliary means for intracranial and extracranial blood flow reconstruction surgery in the treatment of Moyamoya disease. Moreover, in terms of topic selection, iPSC is currently one of the most promising directions for innovative treatment worldwide.

Study Overview

• Status: Recruiting
• Conditions: Moyamoya Disease
• Intervention / Treatment: Biological: iPSC-EVs

Detailed Description

Moyamoya disease is a cerebrovascular disease clinically characterized by chronic progressive stenosis or occlusion at the ends of bilateral internal carotid arteries and the origin of anterior cerebral arteries and middle cerebral arteries, followed by the formation of abnormal vascular networks at the base of the skull. Because this abnormal vascular network at the base of the skull looks like wisps of smoke on cerebral angiography, the Japanese Suzuki first named it "Moyamoya Disease" in the 1960s. Clinically, patients with Moyamoya disease mainly present with ischemic or hemorrhagic stroke, and there are two peaks of incidence in children aged 3-5 and middle-aged people aged 40-50. Epidemiological studies have found that Moyamoya disease is mainly distributed among the population in East Asia, including Japan, South Korea and China, and its incidence rate in China has shown a significant upward trend in recent years.Moreover, as the pathogenesis and treatment evaluation of Moyamoya disease are still in the research trough at present, new discoveries are prone to occur and thus attract a great deal of attention. It not only has a beneficial promoting effect on the treatment and diagnosis of patients, but also makes it easier for research topics to be reported in top journals.

In recent years, with the popularity of IPscs, the emerging therapeutic approach of extracellular vesicles derived from IPscs (iPSC-EVs) has gradually come into the public view. Extracellular vesicles derived from IPscs have specific bioactive substances related to iPSC functions. Their main advantages are manifested as follows: (1) They have a strong ability to promote regeneration and can promote vascular regeneration; (2) It has a powerful function of inhibiting inflammatory responses and can significantly inhibit the release of inflammatory factors by microglia, astrocytes and oligodendrocytes. (3) The homogeneity and stability of IPscs enable extracellular vesicles derived from IPscs to have high drugability; (4) IPscs have good potential for gene editing and can support the engineering of extracellular vesicles and drug delivery in extracellular vesicles. (5) The homing effect of IPSC-differentiated cells can endow the corresponding extracellular vesicles with better tissue-targeting characteristics.

This study intends to combine iPSC-EVs local skin transplantation with temporal muscle application to promote muscle angiogenesis and the establishment of extracranial and intracranial collateral circulation after temporal muscle application. The above-mentioned design features high efficiency, safety and convenience, and is an innovative exploration both at home and abroad. We hope to screen out safe, efficient and simple preparation methods and transplantation methods of iPSC-EVs through systematic experiments, establish an effective clinical evaluation system, and provide auxiliary means for intracranial and extracranial blood flow reconstruction surgery in the treatment of Moyamoya disease. Moreover, in terms of topic selection, iPSC is currently one of the most promising directions for innovative treatment worldwide.

• Study Type: Interventional
• Enrollment (Estimated): 9
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Huaqiu Zhang; Phone Number: 13419632963; Email: lyc@tjh.tjmu.edu.cn

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430030
      • Recruiting
      • Tongji Hospital
      • Contact: Huaqiu Zhang, Clinical Professor; Phone Number: 13419632963; Email: lyc@tjh.tjmu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion criteria:

1. Diagnosed adult patients with MMD aged 18-75 years (inclusive), with bilateral terminal occlusion of the internal carotid arteries (ICA) and stenosis or occlusion of the anterior cerebral artery (ACA) and middle cerebral artery (MCA) at the origin, accompanied by the formation of abnormal vascular networks at the base of the skull, as indicated by head DSA or MRA. Unilateral or bilateral lesions are acceptable. Suzuki score ≥ 3.
2. Relevant bone marrow, liver, kidney, and heart function indicators meet the following standards (based on the normal values of the clinical trial center): absolute neutrophil count (ANC) ≥ 1.5×109/L, platelets ≥ 100×109/L, total serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), ALT, AST, or ALP ≤ 3 times ULN; serum creatinine ≤ 1.5 times ULN, international normalized ratio (INR) ≤ 1.5 times ULN, APTT ≤ 1.5 times ULN.
3. Patients have undergone temporal muscle patch surgery and have not achieved satisfactory improvement in symptoms.
4. Patients have been followed up for ≥ 3 months since the surgery.
5. Vascular DSA performed 3 months after the surgery indicates poor blood flow reconstruction.
6. CTP or ASL performed 3 months after the surgery shows ischemia.
7. Patients still have clinical manifestations of cerebral ischemia or cerebral infarction due to MMD 3 months after the surgery.
8. Patients or their legal representatives have given informed consent and signed the informed consent form.

Exclusion criteria:

1. Patients with severe liver or kidney dysfunction or other complications;
2. Patients with a history of mental disorders or mental diseases;
3. Patients with coagulation disorders;
4. Patients with extensive cerebral infarction or in a coma;
5. Patients who only undergo direct bypass surgery;
6. Patients who have not signed the surgical consent form;
7. Patients with allergic constitutions or a clear history of allergies;
8. Pregnant women, lactating women, and patients with plans to conceive during the trial period;
9. Patients who have participated in other clinical trials in the past three months;
10. Patients deemed unsuitable for the trial by the researcher.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: iPSC-EVs	Biological: iPSC-EVs; iPSC-EVs，The drug number is NouvSoma002-01. It is from iRegene Therapeutics Co., Ltd.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Evaluate the tolerance and adverse reactions of patients after 3 days, 2 weeks and 1 month of iPSC-EVs treatment. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability].	3 Day、2 week、1 month
Imaging examinations	Imaging examinations were conducted on the patients before iPSC-EVs treatment, and at 1 month after treatment. Imaging examinations: MRI and TCD.	1 month
Neuropsychological tests	Neuropsychological tests were conducted on the patients before iPSC-EVs treatment, and at 1 month after treatment. neuropsychological tests: mRS, MMSE and MoCA	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Imaging examinations	Imaging examinations for post-treatment imaging assessment of blood flow reconstruction function. Imaging examinations: DSA, MRI, CTP, TCD, HR-VWI, and CT.	3 month, 6 month, 12 month, and 24 month
Neuropsychological tests	Neuropsychological tests for post-treatment imaging assessment of blood flow reconstruction function. neuropsychological tests: mRS, MMSE and MoCA	3 month, 6 month, 12 month, and 24 month

Collaborators and Investigators

• Sponsor: Huaqiu Zhang
• Investigators: Principal Investigator: Huaqiu Zhang, Tongji Hospital

Study record dates

Study Major Dates

• Study Start (Actual): May 26, 2025
• Primary Completion (Estimated): May 31, 2026
• Study Completion (Estimated): October 31, 2026

Study Registration Dates

• First Submitted: May 9, 2025
• First Submitted That Met QC Criteria: July 3, 2025
• First Posted (Actual): July 15, 2025

Study Record Updates

• Last Update Posted (Estimated): October 1, 2025
• Last Update Submitted That Met QC Criteria: September 29, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Arterial Occlusive Diseases; Intracranial Arterial Diseases; Carotid Artery Diseases; Cerebral Arterial Diseases; Moyamoya Disease
• Other Study ID Numbers: TJ-IRB202503034

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No